NeuroThera Labs Inc. — Investor Relations & Filings
NeuroThera Labs Inc. is a clinical-stage company specializing in the development of therapeutics and advanced technologies for central nervous system (CNS) disorders and brain health. The company operates through two primary development streams. First, it is a leader in photobiomodulation (PBM) technology, developing drug-free, non-invasive devices for neurotherapy, targeting conditions such as Major Depressive Disorder (MDD), Alzheimer’s Disease, and Traumatic Brain Injury (TBI). Second, NeuroThera maintains a pharmaceutical pipeline focused on novel drug candidates, including programs based on THC and proprietary opioid/non-opioid compounds designed to enhance pain relief and treat CNS disorders. This dual approach leverages both advanced medical devices and clinical-stage drug candidates to address prevalent neurological conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| News release - English.pdf | 2026-05-20 | English | |
| News release - English.pdf | 2026-04-30 | English | |
| Other securityholders documents - English.pdf | 2026-04-30 | English | |
| 52-109FV1 - Certification of annual filings - CEO (E).pdf | 2026-04-29 | English | |
| Annual MD&A - English.pdf | 2026-04-29 | English | |
| Audited annual financial statements – English.pdf | 2026-04-29 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47783614 | News release - English.pdf | 2026-05-20 | English | ||
| 47783618 | News release - English.pdf | 2026-04-30 | English | ||
| 47783621 | Other securityholders documents - English.pdf | 2026-04-30 | English | ||
| 47783631 | 52-109FV1 - Certification of annual filings - CEO (E).pdf | 2026-04-29 | English | ||
| 47783639 | Annual MD&A - English.pdf | 2026-04-29 | English | ||
| 47783653 | Audited annual financial statements – English.pdf | 2026-04-29 | English | ||
| 35978885 | News release - English.pdf | 2026-04-24 | English | ||
| 35933133 | News release - English.pdf | 2026-04-24 | English | ||
| 34055105 | Report of voting results.pdf | 2026-04-11 | English | ||
| 34047772 | Report of voting results.pdf | 2026-04-11 | English | ||
| 33221363 | Other securityholders documents - English.pdf | 2026-04-03 | English | ||
| 47783656 | Other securityholders documents - English.pdf | 2026-03-19 | English | ||
| 47783660 | Material change report - English.pdf | 2026-03-19 | English | ||
| 47783684 | Form of proxy - English.pdf | 2026-03-17 | English | ||
| 47783688 | News release - English.pdf | 2026-03-16 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ajanta Pharma Ltd.
Specialty pharmaceutical firm focused on complex generics a…
|
AJANTPHARM | IN | Manufacturing |
|
Akari Therapeutics Plc
Develops next-gen antibody-drug conjugates using proprietar…
|
AKTX | US | Manufacturing |
|
Akebia Therapeutics, Inc.
A biopharmaceutical company that develops and commercialize…
|
AKBA | US | Manufacturing |
|
Akeso, Inc.
Global commercial-stage biopharma developing innovative ant…
|
9926 | KY | Manufacturing |
|
Aktis Oncology, Inc.
A clinical-stage biotech developing targeted alpha radiopha…
|
AKTS | US | Manufacturing |
|
Akums Drugs and Pharmaceuticals Limited
CDMO providing end-to-end pharmaceutical manufacturing and …
|
AKUMS | IN | Manufacturing |
|
Albert David Ltd.
Produces pharmaceutical formulations, infusions, and specia…
|
ALBERTDAVD | IN | Manufacturing |
|
Aldeyra Therapeutics, Inc.
Develops medications for immune-mediated ocular and systemi…
|
ALDX | US | Manufacturing |
|
Aleafia Health Inc.
Vertically integrated cannabis company with cultivation, pr…
|
AH | CA | Manufacturing |
|
Alector, Inc.
Clinical-stage biotech using immuno-neurology to treat neur…
|
ALEC | US | Manufacturing |
NeuroThera Labs Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/48112/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=48112 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=48112 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=48112 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 48112}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NeuroThera Labs Inc. (id: 48112)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.